These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 33001202)

  • 21. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.
    Faridi KF; Garratt KN; Kennedy KF; Maddox TM; Secemsky EA; Butala NM; Yeh RW
    Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e006275. PubMed ID: 32156164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).
    Damman P; Varenhorst C; Koul S; Eriksson P; Erlinge D; Lagerqvist B; James SK
    Am J Cardiol; 2014 Jan; 113(1):64-9. PubMed ID: 24169009
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y
    Abtan J; Ducrocq G; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL
    Circ Cardiovasc Interv; 2019 Mar; 12(3):e007445. PubMed ID: 30871355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal P2Y12 Inhibitor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: A Network Meta-Analysis.
    Rafique AM; Nayyar P; Wang TY; Mehran R; Baber U; Berger PB; Tobis J; Currier J; Dave RH; Henry TD
    JACC Cardiovasc Interv; 2016 May; 9(10):1036-46. PubMed ID: 27198684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Timing of Oral P2Y
    Tarantini G; Mojoli M; Varbella F; Caporale R; Rigattieri S; Andò G; Cirillo P; Pierini S; Santarelli A; Sganzerla P; Cacciavillani L; Babuin L; De Cesare N; Limbruno U; Massoni A; Rognoni A; Pavan D; Belloni F; Cernetti C; Favero L; Saia F; Fovino LN; Masiero G; Roncon L; Gasparetto V; Ferlini M; Ronco F; Rossini R; Canova P; Trabattoni D; Russo A; Guiducci V; Penzo C; Tarantino F; Mauro C; Corrada E; Esposito G; Marchese A; Berti S; Martinato M; Azzolina D; Gregori D; Angiolillo DJ; Musumeci G; ;
    J Am Coll Cardiol; 2020 Nov; 76(21):2450-2459. PubMed ID: 32882390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiplatelet effect of ticagrelor compared to tirofiban in non-ST-segment elevation ACS patients undergoing PCI. The result of the TE-CLOT trial.
    Kim JS; Han DC; Jeong YH; Park DW; Sohn CB; Hwang KW; Lee SH; Choi JH; Chon MK; Lee SY; Hwang J; Kim IS; Lee SM; Han J; Noh M; Kim CH; Chun KJ; Park YH; Kim JH
    Thromb Haemost; 2016 Jan; 115(1):213-21. PubMed ID: 26581884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial.
    Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS
    JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early P2Y12 Inhibitors Escalation in Primary PCI Patients: Insights from the RENOVAMI Registry.
    Lupi A; Bona RD; Meliga E; Capodanno D; Schaffer A; Bongo AS; Gaudio G; Guasti L; Alexopoulos D; Valgimigli M; Porto I
    Thromb Haemost; 2018 May; 118(5):852-863. PubMed ID: 29618159
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contemporary Trends and Outcomes Associated With the Preprocedural Use of Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: Insights From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2).
    Sukul D; Seth M; Dixon SR; Khandelwal A; LaLonde TA; Gurm HS
    J Invasive Cardiol; 2017 Oct; 29(10):340-351. PubMed ID: 28420804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy.
    Porto I; Bolognese L; Dudek D; Goldstein P; Hamm C; Tanguay JF; Ten Berg J; Widimský P; Le Gall N; Zagar AJ; LeNarz LA; Miller D; Montalescot G;
    JACC Cardiovasc Interv; 2016 May; 9(9):897-907. PubMed ID: 27151605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study.
    Qaderdan K; Ishak M; Heestermans AA; de Vrey E; Jukema JW; Voskuil M; de Boer MJ; van't Hof AW; Groenemeijer BE; Vos GJ; Janssen PW; Bergmeijer TO; Kelder JC; Deneer VH; ten Berg JM
    Am Heart J; 2015 Nov; 170(5):981-985.e1. PubMed ID: 26542508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
    Abtan J; Steg PG; Stone GW; Mahaffey KW; Gibson CM; Hamm CW; Price MJ; Abnousi F; Prats J; Deliargyris EN; White HD; Harrington RA; Bhatt DL;
    JACC Cardiovasc Interv; 2016 Sep; 9(18):1905-13. PubMed ID: 27659566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Contemporary antithrombotic strategies in patients with acute coronary syndrome admitted to cardiac care units in Italy: The EYESHOT Study.
    De Luca L; Leonardi S; Cavallini C; Lucci D; Musumeci G; Caporale R; Abrignani MG; Lupi A; Rakar S; Gulizia MM; Bovenzi FM; De Servi S;
    Eur Heart J Acute Cardiovasc Care; 2015 Oct; 4(5):441-52. PubMed ID: 25414322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.
    Ristorto J; Messas N; Marchandot B; Kibler M; Hess S; Meyer N; Schaeffer M; Tuzin N; Ohlmann P; Jesel L; Morel O
    J Atheroscler Thromb; 2018 Aug; 25(8):674-689. PubMed ID: 29415954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry.
    Hoedemaker NPG; Damman P; Ottervanger JP; Dambrink JHE; Gosselink ATM; Kedhi E; Kolkman E; de Winter RJ; van 't Hof AWJ
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):127-138. PubMed ID: 30084902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial.
    Tarantini G; Mojoli M; Varbella F; Caporale R; Rigattieri S; Andò G; Cirillo P; Pierini S; Santarelli A; Sganzerla P; De Cesare N; Limbruno U; Lupi A; Ricci R; Cernetti C; Favero L; Saia F; Roncon L; Gasparetto V; Ferlini M; Ronco F; Ferri L; Trabattoni D; Russo A; Guiducci V; Penzo C; Tarantino F; Mauro C; Marchese A; Castiglioni B; La Manna A; Martinato M; Gregori D; Angiolillo DJ; Musumeci G
    Trials; 2020 Nov; 21(1):966. PubMed ID: 33234137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of potent P2Y12 blockers with ischemic and bleeding outcomes in non-ST-segment elevation myocardial infarction.
    Sim DS; Jeong MH; Kim HS; Gwon HC; Seung KB; Rha SW; Chae SC; Kim CJ; Cha KS; Park JS; Yoon JH; Chae JK; Joo SJ; Choi DJ; Hur SH; Seong IW; Cho MC; Kim DI; Oh SK; Ahn TH; Hwang JY;
    J Cardiol; 2019 Feb; 73(2):142-150. PubMed ID: 30509351
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
    Gan XD; Wei BZ; Fang D; Fang Q; Li KY; Ding SL; Peng S; Wan J
    Curr Med Res Opin; 2015 Dec; 31(12):2313-23. PubMed ID: 26402735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry.
    Godschalk TC; Byrne RA; Adriaenssens T; Malik N; Feldman LJ; Guagliumi G; Alfonso F; Neumann FJ; Trenk D; Joner M; Schulz C; Steg PG; Goodall AH; Wojdyla R; Dudek D; Wykrzykowska JJ; Hlinomaz O; Zaman AG; Curzen N; Dens J; Sinnaeve P; Desmet W; Gershlick AH; Kastrati A; Massberg S; Ten Berg JM;
    JACC Cardiovasc Interv; 2017 Dec; 10(24):2548-2556. PubMed ID: 29268884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry.
    Kurz DJ; Radovanovic D; Seifert B; Bernheim AM; Roffi M; Pedrazzini G; Windecker S; Erne P; Eberli FR
    Eur Heart J Acute Cardiovasc Care; 2016 Feb; 5(1):13-22. PubMed ID: 25614494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.